Manuscripts
Showing 1591 manuscripts.
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206
Citation
Marisa T. Tungsiripat, M.D., Doug Kitch, M.S., Marshall Jay Glesby, M.D., Ph.D., Samir K. Gupta, M.D., John W. Mellors, M.D., Laura E. Moran, M.P.H., Lynne Jones, B.S., Beverly L. Alston-Smith, M.D., James F. Rooney, M.D., Judith A. Aberg, M.D. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS. 2010 Jul 17; 24(11):1781-4. PMID: 20495438; PMCID: PMC2913151.Year
2010
Journal
AIDS
Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087
Citation
Carl J. Fichtenbaum, M.D., Tzu-min Yeh, Scott Evans, Ph.D., Judith A. Aberg, M.D. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. Journal of Clinical Lipidology. 2010 Jul 01; 4(4):279-87. PMID: 20824151; PMCID: PMC2932453.Year
2010
Journal
Journal of Clinical Lipidology
Measurement of antiretroviral drugs in the lungs of HIV-infected patients
Citation
Homer L. Twigg, III, M.D., Carol T Schnizlein Bick, Ph.D., Michael D. Weiden, M.D., Fred T. Valentine, M.D., L. Joseph Wheat, M.D., Richard B. Day, B.S., Helen C. Rominger-Grubbs, R.N., M.S.N, F.N.P., C.C.R.C., Lu (Summer) Zheng, Ph.D., Ronald G. Collman, M.D., Robert W. Coombs, M.D., Ph.D., R. Pat Bucy, M.D., Ph.D., Naser L. Rezk, Ph.D., Angela D.M. Kashuba, Pharm.D. Measurement of antiretroviral drugs in the lungs of HIV-infected patients. HIV Therapy. 2010 Mar 01; 4(2):247-51. PMID: 20436781; PMCID: PMC2861507.Year
2010
Journal
HIV Therapy
Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection
Citation
Judith J. Lok, Ph.D., Ronald J. Bosch, Ph.D., Constance A. Benson, M.D., Ann C. Collier, M.D., Gregory K. Robbins, M.D., M.P.H., Robert Shafer, M.D. Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS. 2010 Jul 31; 24(12):1867-76. PMID: 20467286; PMCID: PMC3018341.Year
2010
Journal
AIDS
Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188
Citation
Lori Kamemoto, M.D., M.P.H., Susan Ellen Cohn, M.D., M.P.H., Mary A. Vogler, M.D., Kristine Patterson, M.D., Lori Kamemoto, M.D., M.P.H., Jeong-Gun Park, Ph.D., Heather D. Watts, M.D., Francesca Aweeka, Pharm.D., Karin L. Klingman, M.D., Apsara Nair, M.S., Song Yu, M.S., Susan Ellen Cohn, M.D., M.P.H. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. Journal of Acquired Immune Deficiency Syndromes. 2010 Dec 01; 55(4):473-82. PMID: 20842042.Year
2010
Journal
Journal of Acquired Immune Deficiency Syndromes
Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211.
Citation
Tzu-min Yeh, Scott Evans, Ph.D., Roy (Trip) Gulick, M.D., M.P.H., David B. Clifford, M.D. Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211. HIV Clinical Trials. 2010 Jan 01; 11(1):51-8. PMID: 20400411; PMCID: PMC2958041.Year
2010
Journal
HIV Clinical Trials
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
Citation
Roger Paredes, Christina M. Lalama, M.S., Heather Ribaudo, Ph.D., Bruce R. Schackman, Ph.D., Cecilia M. Shikuma, M.D., Francoise Giguel, William A. Meyer, III, Ph.D., Victoria A. Johnson, M.D., Susan A. Fiscus, Ph.D., Richard T. D'Aquila, M.D., Roy (Trip) Gulick, M.D., M.P.H., Daniel R. Kuritzkes, M.D. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. Journal of Infectious Diseases. 2010 Mar 01; 201(5):662-71. PMID: 20102271; PMCID: PMC2825289.Year
2010
Journal
Journal of Infectious Diseases
Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection.
Citation
Philip Grant, M.D., Lauren Komarow, M.S., Janet Andersen, Sc.D., Irini Sereti, M.D., Savita G. Pahwa, M.D., Michael M. Lederman, M.D., Joseph J. Eron, Jr., M.D., Ian M. Sanne, M.D., FCP (medicine), DTM&H, William G. Powderly, M.D., Evelyn Hogg, B.A., Carol Suckow, B.S.N., Andrew R. Zolopa, M.D. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. Public Library of Science One. 2010 Jul 01; 5(7):e11416. PMID: 20617176; PMCID: PMC2895658.Year
2010
Journal
Public Library of Science One
Early antiretroviral therapy for patients with acute AIDS-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164
Citation
Early antiretroviral therapy for patients with acute AIDS-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. HIV Clinical Trials. 2010 Sep 01; 11(5):248-59. PMID: 21126955; PMCID: PMC3183461.Year
2010
Journal
HIV Clinical Trials
Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy
Citation
Todd T. Brown, M.D., Katherine Tassiopoulos, Sc.D., M.P.H., Ronald J. Bosch, Ph.D., Cecilia M. Shikuma, M.D., Grace McComsey, M.D. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care. 2010 Oct 01; 33(10):2244-9. PMID: 20664016; PMCID: PMC2945167.Year
2010
Journal
Diabetes Care